Inspire Pharmaceuticals has completed patient enrollment in three of its late-stage clinical trials.
The milestones have been reached in its TIGER-2 phase III trial testing denufosol tetrasodium for cystic fibrosis, its phase III trial with PROLACRIA for the treatment of dry eye disease and AZASITE (azithromycin ophthalmic solution) for the blepharitis phase II programme.
Go deeper with GlobalData
Inspire executive vice-president and chief, research and development Benjamin Yerxa said that the company was on track to deliver results within 18 months.
“We are pleased to be executing on our strategic plan with the achievement of these patient enrollment milestones in the clinical development programmes for denufosol, PROLACRIA and AZASITE, as this places us in a position to have top-line results from all our late-stage clinical programmes within 18 months,” Yerxa said.
